

Rohit Mehra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5724684/publications.pdf>

Version: 2024-02-01

172
papers

21,076
citations

31949

53
h-index

9854

141
g-index

173
all docs

173
docs citations

173
times ranked

21198
citing authors

#	ARTICLE	IF	CITATIONS
1	Precursors of urinary bladder cancer: molecular alterations and biomarkers. <i>Human Pathology</i> , 2023, 133, 5-21.	1.1	2
2	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e1-4.e7.	0.8	2
3	Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts. <i>Modern Pathology</i> , 2022, 35, 697-704.	2.9	9
4	Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. <i>European Urology Oncology</i> , 2022, 5, 92-99.	2.6	5
5	Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. <i>Asian Journal of Urology</i> , 2022, 9, 1-11.	0.5	11
6	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. <i>European Urology Open Science</i> , 2022, 35, 74-78.	0.2	4
7	Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations. <i>Modern Pathology</i> , 2022, 35, 296-297.	2.9	13
8	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. <i>Nature</i> , 2022, 601, 434-439.	13.7	110
9	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	0.5	4
10	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. <i>BMC Cancer</i> , 2022, 22, 494.	1.1	8
11	Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	0.7	2
12	De novo neuroendocrine features in prostate cancer. <i>Human Pathology</i> , 2022, 127, 112-122.	1.1	7
13	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	1.2	143
14	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	0.8	6
15	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
16	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	0.8	52
17	In Vivo Evaluation of a Novel Pigtail Suture Stent. <i>Urology</i> , 2021, 148, 83-87.	0.5	10
18	Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	142

#	ARTICLE	IF	CITATIONS
19	A novel ATXN1-DUX4 fusion expands the spectrum of "CIC-rearranged sarcoma"™ of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , 2021, 141, 619-622.	3.9	16
20	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	2.9	118
21	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	1.2	18
22	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
23	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	2.9	138
24	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1596-1607.	2.9	17
25	Immunohistochemical expression of PAX8 , PAX2 , and cytokeratin in melanomas. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1246-1251.	0.7	6
26	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	136
27	Characterization of SARS-CoV-2 and host entry factors distribution in a COVID-19 autopsy series. <i>Communications Medicine</i> , 2021, 1, .	1.9	16
28	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	1.0	14
29	Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 450-462.	2.1	7
30	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
31	Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. <i>Oncogene</i> , 2020, 39, 204-218.	2.6	29
32	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020, 33, 1165-1171.	2.9	18
33	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 152663.	1.0	1
34	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	1.2	21
35	Should all prostate needle biopsy Gleason score 4+4=8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e1-78.e6.	0.8	6
36	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , 2020, 145, 204-210.	0.5	3
38	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
39	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
40	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	0.9	10
41	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
42	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
43	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , 2020, 37, 16.	1.2	13
44	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
45	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. <i>European Urology</i> , 2020, 78, 63-74.	0.9	57
46	Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1778.	5.8	50
47	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 332-339.e2.	0.9	5
48	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. <i>JCO Precision Oncology</i> , 2020, 4, 1386-1392.	1.5	4
49	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	1.2	15
50	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
51	A Family With a Carotid Body Paraganglioma and Thyroid Neoplasias With a New SDHAF2 Germline Variant. <i>Journal of the Endocrine Society</i> , 2019, 3, 2151-2157.	0.1	6
52	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. <i>Diagnostic Pathology</i> , 2019, 14, 113.	0.9	8
53	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
54	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.4	247

#	ARTICLE	IF	CITATIONS
55	TFEB Expression Profiling in Renal Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1445-1461.	2.1	38
56	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
57	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1477-1491.	1.2	9
58	The utility of upper urinary tract urine cytology before and after application of the Paris system. <i>Diagnostic Cytopathology</i> , 2019, 47, 421-427.	0.5	19
59	Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. <i>Modern Pathology</i> , 2019, 32, 701-709.	2.9	29
60	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019, 86, 76-84.	1.1	16
61	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , 2019, 36, 27.	1.2	8
62	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. <i>Journal of Urology</i> , 2019, 201, 284-291.	0.2	18
63	Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. <i>Urology</i> , 2018, 117, 95-100.	0.5	26
64	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	1.2	3
65	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	0.9	29
66	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	2.1	101
67	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	1.9	119
68	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	1.3	24
69	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. <i>Human Pathology</i> , 2018, 71, 47-54.	1.1	39
70	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018, 16, 1125-1137.	1.5	51
71	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , 2018, 31, 179-197.	2.9	73
72	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54

#	ARTICLE	IF	CITATIONS
73	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 763-769.	0.9	63
74	Comparative study of <i>TERT</i> promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. <i>Histopathology</i> , 2018, 72, 354-356.	1.6	14
75	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	2.1	34
76	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	0.8	162
77	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169
78	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
79	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. <i>Medical Oncology</i> , 2018, 35, 152.	1.2	13
80	Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1164-1176.	1.2	9
81	Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1202-1215.	1.2	39
82	Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples. <i>Cancer Cytopathology</i> , 2018, 126, 992-1002.	1.4	9
83	An Insight into the "Dark Matter" of Kidney Cancer. <i>European Urology</i> , 2018, 74, 764-766.	0.9	1
84	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
85	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 483-486.	0.9	86
86	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018, 74, 741-753.	0.9	54
87	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , 2018, 74, 529-531.	0.9	17
88	Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC). <i>American Journal of Surgical Pathology</i> , 2018, 42, 1156-1165.	2.1	42
89	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	2.1	22
90	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017, 3, 502-509.	1.6	25

#	ARTICLE	IF	CITATIONS
91	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 726-732.	0.4	11
92	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	1.3	10
93	A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. <i>Histopathology</i> , 2017, 71, 42-52.	1.6	79
94	Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. <i>American Journal of Surgical Pathology</i> , 2017, 41, 801-809.	2.1	33
95	Nephrogenic adenoma does not express NKX3.1. <i>Histopathology</i> , 2017, 71, 669-671.	1.6	9
96	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	1.0	15
97	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. <i>Clinical Cancer Research</i> , 2017, 23, 5622-5630.	3.2	31
98	Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. <i>Human Pathology</i> , 2017, 67, 134-145.	1.1	38
99	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017, 13, 154-157.	0.1	4
100	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017, 171, 1559-1572.e20.	13.5	200
101	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 695-699.	1.0	0
102	Robotic-assisted Thoracoscopic Transdiaphragmatic Adrenalectomy (RATTA) for Metastatic Renal Cell Carcinoma. <i>Urology</i> , 2017, 105, 9-12.	0.5	1
103	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.2	76
104	Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities. <i>Journal of Clinical Oncology</i> , 2017, 35, 296-296.	0.8	2
105	Involvement of p38-TrCP-Tristetraprolin-TNF axis in radiation pneumonitis. <i>Oncotarget</i> , 2017, 8, 47767-47779.	0.8	9
106	Independent surgical validation of the new prostate cancer grade grouping system. <i>BJU International</i> , 2016, 118, 763-769.	1.3	48
107	Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. <i>Prostate</i> , 2016, 76, 845-853.	1.2	9
108	Comprehensive Immunophenotypic Characterization of Adult and Fetal Testes, the Excretory Duct System, and Testicular and Epididymal Appendages. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, e50-e68.	0.6	20

#	ARTICLE	IF	CITATIONS
109	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 489-499.	2.3	55
110	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	0.8	18
111	Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. <i>American Journal of Surgical Pathology</i> , 2016, 40, 865-875.	2.1	182
112	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016, 6, 1258-1266.	7.7	66
113	Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis – Value of Autopsy in a Case Report. <i>Urology Case Reports</i> , 2016, 9, 37-40.	0.1	0
114	Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1026-1037.	1.2	53
115	Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1457-1472.	2.1	112
116	Renal Cell Carcinoma Occurring in Patients With Prior Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 989-997.	2.1	31
117	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	9.4	143
118	Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. <i>Cancer Research</i> , 2016, 76, 1391-1402.	0.4	62
119	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.2	89
120	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <i>European Urology Focus</i> , 2016, 1, 265-268.	1.6	45
121	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , 2016, 70, 549-552.	0.9	121
122	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. <i>Modern Pathology</i> , 2016, 29, 157-165.	2.9	31
123	MP1-14 DEFINING ADVERSE PATHOLOGY FOR LOWER RISK MEN UNDERGOING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2015, 193, .	0.2	1
124	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
125	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.4	94
126	Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 297-311.	1.4	43

#	ARTICLE	IF	CITATIONS
127	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	0.5	12
128	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 549-557.	2.1	43
129	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	3.2	56
130	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , 2015, 25, 1372-1381.	2.4	139
131	Metastases to the kidney: a clinicopathological study of 43 cases with an emphasis on deceptive features. <i>Histopathology</i> , 2015, 66, 587-597.	1.6	32
132	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. <i>Urology Case Reports</i> , 2015, 3, 98-100.	0.1	2
133	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	1.2	10
134	MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1224-1233.	1.2	55
135	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , 2015, 75, 3720-3727.	0.4	276
136	Emerging Entities in Renal Neoplasia. <i>Surgical Pathology Clinics</i> , 2015, 8, 623-656.	0.7	21
137	Investigating the long noncoding RNA SchLAP1 as a prognostic tissue and urine biomarker in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7-7.	0.8	1
138	Prognostic significance of perineural invasion in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 30-30.	0.8	0
139	Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 313-313.	0.8	2
140	A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SchLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. <i>Neoplasia</i> , 2014, 16, 1121-1127.	2.3	81
141	Frequent discordance between <i>ERG</i> gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1199-1208.	1.2	33
142	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SchLAP1. <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	5.1	226
143	Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, Tj ETQq1 1, 0.784314 rgBT /Cv	2.1	31
144	Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC). <i>American Journal of Surgical Pathology</i> , 2014, 38, 567-577.	2.1	48

#	ARTICLE	IF	CITATIONS
145	Tuberous Sclerosis-associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	2.1	211
146	Current and Proposed Molecular Diagnostics in a Genitourinary Service Line Laboratory at a Tertiary Clinical Institution. Cancer Journal (Sudbury, Mass), 2014, 20, 29-42.	1.0	16
147	Primary Urethral Clear-Cell Adenocarcinoma. American Journal of Pathology, 2014, 184, 584-591.	1.9	46
148	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Human Pathology, 2014, 45, 1139-1146.	1.1	25
149	HRAS mutations are frequent in inverted urothelial neoplasms. Human Pathology, 2014, 45, 1957-1965.	1.1	39
150	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. Urology, 2014, 84, 373-379.	0.5	14
151	Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood, 2014, 124, 142-150.	0.6	52
152	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Translational Oncology, 2013, 6, 405-412.	1.7	13
153	Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 2013, 119, 3287-3294.	2.0	51
154	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	13.7	2,128
155	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	7.7	397
156	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3924-3932.	3.2	69
157	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia, 2010, 12, 590-IN21.	2.3	305
158	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology, 2009, 22, 1083-1093.	2.9	209
159	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	13.7	6
160	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	2.3	608
161	Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.4	249
162	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.4	244

#	ARTICLE	IF	CITATIONS
163	Heterogeneity of <i>TPRSS2</i> Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. <i>Cancer Research</i> , 2007, 67, 7991-7995.	0.4	197
164	Comprehensive assessment of <i>TPRSS2</i> and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007, 20, 538-544.	2.9	281
165	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	13.7	743
166	<i>TPRSS2:ETV4</i> Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 3396-3400.	0.4	432
167	Recurrent Fusion of <i>TPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	6.0	3,541
168	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005, 8, 393-406.	7.7	731
169	Identification of <i>GATA3</i> as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. <i>Cancer Research</i> , 2005, 65, 11259-11264.	0.4	272
170	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.4	816
171	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. <i>Oncotarget</i> , 0, 7, 41217-41232.	0.8	57
172	Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin. <i>American Journal of Surgical Pathology</i> , 0, Publish Ahead of Print, .	2.1	0